JP6095366B2 - 疲労を治療又は予防するための方法 - Google Patents

疲労を治療又は予防するための方法 Download PDF

Info

Publication number
JP6095366B2
JP6095366B2 JP2012517622A JP2012517622A JP6095366B2 JP 6095366 B2 JP6095366 B2 JP 6095366B2 JP 2012517622 A JP2012517622 A JP 2012517622A JP 2012517622 A JP2012517622 A JP 2012517622A JP 6095366 B2 JP6095366 B2 JP 6095366B2
Authority
JP
Japan
Prior art keywords
compound
group
sleep
fatigue
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012517622A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530779A5 (ref
JP2012530779A (ja
Inventor
カイララー，モイス，エー．
ブリーム，ガリー
バッツ，ステフェン，イー．
メルニック，スーザン，マリー
タイラー，ダンカン
Original Assignee
エスケー バイオファーマシューティカルズ カンパニー リミテッド
エスケー バイオファーマシューティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスケー バイオファーマシューティカルズ カンパニー リミテッド, エスケー バイオファーマシューティカルズ カンパニー リミテッド filed Critical エスケー バイオファーマシューティカルズ カンパニー リミテッド
Publication of JP2012530779A publication Critical patent/JP2012530779A/ja
Publication of JP2012530779A5 publication Critical patent/JP2012530779A5/ja
Application granted granted Critical
Publication of JP6095366B2 publication Critical patent/JP6095366B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012517622A 2009-06-22 2010-06-21 疲労を治療又は予防するための方法 Active JP6095366B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015134556A Division JP6368285B2 (ja) 2009-06-22 2015-07-03 疲労を治療又は予防するための方法

Publications (3)

Publication Number Publication Date
JP2012530779A JP2012530779A (ja) 2012-12-06
JP2012530779A5 JP2012530779A5 (ref) 2015-01-15
JP6095366B2 true JP6095366B2 (ja) 2017-03-15

Family

ID=43429751

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012517622A Active JP6095366B2 (ja) 2009-06-22 2010-06-21 疲労を治療又は予防するための方法
JP2015134556A Active JP6368285B2 (ja) 2009-06-22 2015-07-03 疲労を治療又は予防するための方法
JP2018128318A Pending JP2018188450A (ja) 2009-06-22 2018-07-05 疲労を治療又は予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015134556A Active JP6368285B2 (ja) 2009-06-22 2015-07-03 疲労を治療又は予防するための方法
JP2018128318A Pending JP2018188450A (ja) 2009-06-22 2018-07-05 疲労を治療又は予防するための方法

Country Status (12)

Country Link
US (5) US8741950B2 (ref)
EP (1) EP2445490B1 (ref)
JP (3) JP6095366B2 (ref)
KR (3) KR102021075B1 (ref)
CN (2) CN102481274A (ref)
AU (1) AU2010270971B2 (ref)
BR (1) BRPI1015233A2 (ref)
IN (1) IN2012DN00624A (ref)
MX (1) MX2012000034A (ref)
RU (1) RU2567801C2 (ref)
TW (1) TWI453014B (ref)
WO (1) WO2011005473A2 (ref)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
MX2012000034A (es) 2009-06-22 2012-02-21 Sk Biopharmaceuticals Co Ltd Metodos para el tratamiento o la prevencion de la fatiga.
US8927602B2 (en) * 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9060994B2 (en) 2011-12-21 2015-06-23 Inno Biosciences, S.p.A. Combination therapy with interferon and andrographolides for Multiple Sclerosis
PT2968208T (pt) 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
JP2016530240A (ja) * 2013-07-12 2016-09-29 ジャズ ファーマスティカルズ インターナショナル スリー リミテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｉｉ Ｌｉｍｉｔｅｄ 禁煙の促進
US9226910B2 (en) 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
JP6742904B2 (ja) * 2013-11-08 2020-08-19 レガシー ヘルスケア リミテッド ガンおよびガン共存症の治療に使用するための組成物
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
SG11201901998WA (en) 2016-09-06 2019-04-29 Jazz Pharmaceuticals International Iii Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN110049966A (zh) * 2016-10-06 2019-07-23 杰资制药国际三期有限公司 氨基甲酰基苯丙氨醇化合物及其用途
CN110139905B (zh) * 2016-12-30 2021-09-28 株式会社东进世美肯 涂层组合物及由此制备的薄膜
BR112019025286A2 (pt) 2017-06-02 2020-06-23 Jazz Pharmaceuticals Ireland Limited Métodos e composições para tratamento de sonolência excessiva
WO2019027941A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals International Iii Limited CARBAMOYL PHENYLALANINOL ANALOGUES AND USES THEREOF
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2022390879A1 (en) * 2021-11-16 2024-06-13 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
KR20260033050A (ko) 2023-06-29 2026-03-10 액섬 테라퓨틱스, 인크. 수유 여성에게 솔리암페톨을 투여하는 방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
WO1998015526A1 (en) * 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
PL1890684T3 (pl) 2005-06-08 2014-05-30 Sk Biopharmaceuticals Co Ltd Leczenie zaburzeń snu i czuwania
ES2344469T3 (es) 2005-06-22 2010-08-27 Sk Holdings Co., Ltd. Tratamiento de disfuncion sexual.
BRPI0520451A2 (pt) 2005-07-26 2009-05-12 Janssen Pharmaceutica Nv métodos para tratamento de distúrbios associados a substáncias quìmicas
EA200970377A1 (ru) 2006-10-13 2009-10-30 Янссен Фармацевтика Нв Композиции фенилалкиламинокарбамата
MX2012000034A (es) * 2009-06-22 2012-02-21 Sk Biopharmaceuticals Co Ltd Metodos para el tratamiento o la prevencion de la fatiga.
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
PT2968208T (pt) * 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Also Published As

Publication number Publication date
JP6368285B2 (ja) 2018-08-01
AU2010270971B2 (en) 2015-08-20
US20140243406A1 (en) 2014-08-28
KR20120098578A (ko) 2012-09-05
EP2445490A4 (en) 2019-10-23
CA2765463C (en) 2018-10-09
CA2765463A1 (en) 2011-01-13
IN2012DN00624A (ref) 2015-06-12
US20120142769A1 (en) 2012-06-07
KR20190105675A (ko) 2019-09-17
BRPI1015233A2 (pt) 2018-02-20
JP2018188450A (ja) 2018-11-29
CN106727486A (zh) 2017-05-31
AU2010270971A1 (en) 2012-01-19
US20200061017A1 (en) 2020-02-27
MX2012000034A (es) 2012-02-21
TWI453014B (zh) 2014-09-21
US9999609B2 (en) 2018-06-19
JP2015214564A (ja) 2015-12-03
JP2012530779A (ja) 2012-12-06
RU2567801C2 (ru) 2015-11-10
CN102481274A (zh) 2012-05-30
RU2012101947A (ru) 2013-07-27
WO2011005473A2 (en) 2011-01-13
US20180263950A1 (en) 2018-09-20
EP2445490B1 (en) 2023-02-08
KR102173587B1 (ko) 2020-11-04
US8741950B2 (en) 2014-06-03
US10507192B2 (en) 2019-12-17
EP2445490A2 (en) 2012-05-02
KR20170086710A (ko) 2017-07-26
US20170000756A1 (en) 2017-01-05
WO2011005473A9 (en) 2011-05-12
TW201105320A (en) 2011-02-16
US9464041B2 (en) 2016-10-11
KR102021075B1 (ko) 2019-11-04

Similar Documents

Publication Publication Date Title
JP6368285B2 (ja) 疲労を治療又は予防するための方法
ES2216327T3 (es) Uso de iminoazucares alquilados para tratar la resistencia a multiples a farmacos.
KR102272274B1 (ko) (ｓ)-3-(4-((4-(모르폴리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온의 제제
CA3050553A1 (en) Therapeutic modifiers of the reverse mode of atp synthase
AU2019208238A1 (en) Therapeutic Modifiers of the Reverse Mode of ATP Synthase
JP2023181398A (ja) 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
JP2013515073A (ja) （メチルスルホニル）エチルベンゼンイソインドリン誘導体及びその治療的使用
US9248098B2 (en) Treating or preventing pain using spicamycin derivatives
US20140045780A1 (en) Compositions comprising spicamycin derivatives and methods of use thereof
CA2765463E (en) Methods for treating or preventing fatigue
HK1234314A1 (en) Methods for treating or preventing fatigue
HK1171657A (en) Methods for treating or preventing fatigue
Upadhyaya et al. Role of an indigenous drug Geriforte on blood levels of biogenic amines and its significance in the treatment of anxiety neurosis
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
US20250009766A1 (en) Cannabigerol for treatment of seizures and epilepsy
KR20250164296A (ko) 우울증의 치료를 위한 5-메톡시-2-아미노인단을 포함하는 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141016

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141023

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161012

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170214

R150 Certificate of patent or registration of utility model

Ref document number: 6095366

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250